111 related articles for article (PubMed ID: 15559851)
1. Growth inhibition of MCF-7 tumor cell line by phenylacetate linked to functionalized dextran.
Frank L; Avramoglou T; Sainte-Catherine O; Jozefonvicz J; Kraemer M
J Biomater Sci Polym Ed; 2004; 15(10):1305-15. PubMed ID: 15559851
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of human melanoma tumor cells by the combination of sodium phenylacetate (NaPA) and substituted dextrans and one NaPA-dextran conjugate.
Gervelas C; Avramoglou T; Crépin M; Jozefonvicz J
Anticancer Drugs; 2002 Jan; 13(1):37-45. PubMed ID: 11914639
[TBL] [Abstract][Full Text] [Related]
3. Sodium phenylacetate enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice.
Di Benedetto M; Kourbali Y; Starzec A; Vassy R; Jozefonvicz J; Perret G; Crepin M; Kraemer M
Br J Cancer; 2001 Sep; 85(6):917-23. PubMed ID: 11556846
[TBL] [Abstract][Full Text] [Related]
4. Aponecrotic, antiangiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vitro and in vivo.
Di Benedetto M; Starzec A; Colombo BM; Briane D; Perret GY; Kraemer M; Crépin M
Br J Pharmacol; 2002 Apr; 135(8):1859-71. PubMed ID: 11959788
[TBL] [Abstract][Full Text] [Related]
5. Sodium phenylacetate modulates the synthesis of autocrine and paracrine growth factors secreted by breast cancer cell lines.
Thibout D; Di Benedetto M; Kraemer M; Sainte-Catherine O; Derbin C; Crépin M
Anticancer Res; 1998; 18(4A):2657-61. PubMed ID: 9703924
[TBL] [Abstract][Full Text] [Related]
6. Sodium phenylacetate (NaPa) induces modifications of the proliferation, the adhesion and the cell cycle of tumoral epithelial breast cells.
Thibout D; Kraemer M; Di Benedetto M; Saffar L; Gattegno L; Derbin C; Crépin M
Anticancer Res; 1999; 19(3A):2121-6. PubMed ID: 10470159
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro.
Ferrandina G; Melichar B; Loercher A; Verschraegen CF; Kudelka AP; Edwards CL; Scambia G; Kavanagh JJ; Abbruzzese JL; Freedman RS
Cancer Res; 1997 Oct; 57(19):4309-15. PubMed ID: 9331092
[TBL] [Abstract][Full Text] [Related]
8. Decrease of breast cancer cell invasiveness by sodium phenylacetate (NaPa) is associated with an increased expression of adhesive molecules.
Vasse M; Thibout D; Paysant J; Legrand E; Soria C; Crépin M
Br J Cancer; 2001 Mar; 84(6):802-7. PubMed ID: 11259095
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination.
Adam L; Crépin M; Isräel L
Cancer Res; 1997 Mar; 57(6):1023-9. PubMed ID: 9067263
[TBL] [Abstract][Full Text] [Related]
10. Cytostatic and pro-apoptotic effects of a novel phenylacetate-dextran derivative (NaPaC) on breast cancer cells in interactions with endothelial cells.
Malherbe S; Crépin M; Legrand C; Wei MX
Anticancer Drugs; 2004 Nov; 15(10):975-81. PubMed ID: 15514567
[TBL] [Abstract][Full Text] [Related]
11. Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation.
Hudgins WR; Shack S; Myers CE; Samid D
Biochem Pharmacol; 1995 Oct; 50(8):1273-9. PubMed ID: 7488244
[TBL] [Abstract][Full Text] [Related]
12. Modulation by phenylacetate of early estrogen-mediated events in MCF-7 breast cancer cells.
Liu J; Li J; Sidell N
Cancer Chemother Pharmacol; 2007 Feb; 59(2):217-25. PubMed ID: 16738884
[TBL] [Abstract][Full Text] [Related]
13. Sodium phenylacetate inhibits the Ras/MAPK signaling pathway to induce reduction of the c-Raf-1 protein in human and canine breast cancer cells.
Watanabe M; Miyajima N; Igarashi M; Endo Y; Watanabe N; Sugano S
Breast Cancer Res Treat; 2009 Nov; 118(2):281-91. PubMed ID: 18953652
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of estrogen-dependent breast cell responses with phenylacetate.
Sawatsri S; Samid D; Malkapuram S; Sidell N
Int J Cancer; 2001 Sep; 93(5):687-92. PubMed ID: 11477579
[TBL] [Abstract][Full Text] [Related]
15. Suppression of tumourigenicity, and induction of differentiation of the canine mammary tumour cell line MCM-B2 by sodium phenylacetate.
Watanabe M; Sugano S; Imai J; Yoshida K; Onodera R; Amin MR; Uchida K; Yamaguchi R; Tateyama S
Res Vet Sci; 2001 Feb; 70(1):27-32. PubMed ID: 11170848
[TBL] [Abstract][Full Text] [Related]
16. Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function.
Kebebew E; Wong MG; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1999 Aug; 84(8):2840-7. PubMed ID: 10443689
[TBL] [Abstract][Full Text] [Related]
17. Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma.
Harrison LE; Wojciechowicz DC; Brennan MF; Paty PB
Surgery; 1998 Sep; 124(3):541-50. PubMed ID: 9736908
[TBL] [Abstract][Full Text] [Related]
18. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene.
Danesi R; Nardini D; Basolo F; Del Tacca M; Samid D; Myers CE
Mol Pharmacol; 1996 Jun; 49(6):972-9. PubMed ID: 8649357
[TBL] [Abstract][Full Text] [Related]
19. A prenylation inhibitor (sodium phenylacetate) differently affects MCF-7 cell death when ras is overexpressed, partly involving P42/44, JNK and P38 kinase activations.
Di Benedetto M; Crépin M; Kraemer M; Oudar O
Anticancer Res; 2008; 28(2A):1029-37. PubMed ID: 18507051
[TBL] [Abstract][Full Text] [Related]
20. A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects.
Sebbah-Louriki M; Colombo BM; el Manouni D; Martin A; Salzmann JL; Leroux Y; Perret GY; Crépin M
Anticancer Res; 2002; 22(6C):3925-31. PubMed ID: 12553014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
